0001384101-19-000152.txt : 20191204
0001384101-19-000152.hdr.sgml : 20191204
20191204162222
ACCESSION NUMBER: 0001384101-19-000152
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20191202
FILED AS OF DATE: 20191204
DATE AS OF CHANGE: 20191204
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kennedy Giulia C
CENTRAL INDEX KEY: 0001769333
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36156
FILM NUMBER: 191268433
MAIL ADDRESS:
STREET 1: 338 MAIN STREET #26E
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94105
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERACYTE, INC.
CENTRAL INDEX KEY: 0001384101
STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071]
IRS NUMBER: 205455398
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 6000 SHORELINE COURT, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: (650) 243-6300
MAIL ADDRESS:
STREET 1: 6000 SHORELINE COURT, SUITE 300
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: CALDEROME INC
DATE OF NAME CHANGE: 20061219
4
1
wf-form4_157549452516750.xml
FORM 4
X0306
4
2019-12-02
0
0001384101
VERACYTE, INC.
VCYT
0001769333
Kennedy Giulia C
6000 SHORELINE COURT
SUITE 300
SOUTH SAN FRANCISCO
CA
94080
0
1
0
0
Chief Scientific & Med Officer
Common Stock
2019-12-02
4
F
0
292
27.19
D
47157
D
Common Stock
2019-12-03
4
M
0
3751
6.45
A
50908
D
Common Stock
2019-12-03
4
M
0
1563
5.43
A
52471
D
Common Stock
2019-12-03
4
M
0
5312
9.05
A
57783
D
Common Stock
2019-12-03
4
M
0
4406
5.98
A
62189
D
Common Stock
2019-12-03
4
S
0
15327
26.4672
D
46862
D
Stock Option (right to buy)
6.45
2019-12-03
4
M
0
3751
0
D
2026-02-28
Common Stock
3751.0
3752
D
Stock Option (right to buy)
5.43
2019-12-03
4
M
0
1563
0
D
2026-03-14
Common Stock
1563.0
2085
D
Stock Option (right to buy)
9.05
2019-12-03
4
M
0
5312
0
D
2027-03-02
Common Stock
5312.0
26563
D
Stock Option (right to buy)
5.98
2019-12-03
4
M
0
4406
0
D
2028-03-01
Common Stock
4406.0
39657
D
The reporting person is reporting the withholding of 292 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 587 Restricted Stock Units granted on March 2, 2018 and does not represent a sale by the reporting person.
The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019.
Represents weighted average sales price. Sale prices for the transactions range from $25.99 to $26.94. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
The option became exercisable as to 25% of the shares on March 1, 2017, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.
The option became exercisable as to 25% of the shares on March 15, 2017, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.
The option became exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.
The option became exercisable as to 25% of the shares on March 2, 2019, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter.
/s/ Keith Kennedy as attorney-in-fact
2019-12-04